1-hydroxy-9-methylpurin-6-imine | 10184-51-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 1-hydroxy-9-methylpurin-6-imine
• 英文别名: 9-methyl-1-oxy-9H-purin-6-ylamine
• CAS: 10184-51-7
• 化学式: C₆H₇N₅O
• 分子量: 165.154
• InChiKey: XRJABOXWAYIICL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.82
• 重原子数：
  12.0
• 可旋转键数：
  0.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  83.67
• 氢给体数：
  1.0
• 氢受体数：
  5.0

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1-hydroxy-9-methylpurin-6-imine 在 palladium on activated charcoal sodium perchlorate 、 氢气 作用下， 以 乙醇 、 N,N-二甲基乙酰胺 、 水 为溶剂， 反应 12.5h， 生成 9-甲基腺嘌呤
  参考文献：
  名称：

  Fujii, Tozo; Itaya, Taisuke; Saito, Tohru, Chemical and pharmaceutical bulletin, 1984, vol. 32, # 12, p. 4842 - 4851

  摘要：

  DOI：
• 作为产物：
  描述：

  9-甲基腺嘌呤 在 间氯过氧苯甲酸 作用下， 以 甲醇 为溶剂， 以50%的产率得到1-hydroxy-9-methylpurin-6-imine
  参考文献：
  名称：

  Synthesis and Antiviral Evaluation of Analogs of Adenosine-N¹-Oxide and 1-(Benzyloxy)Adenosine

  摘要：

  The application of recombinant DNA technology to vaccinia virus for the purpose of developing vaccines dates back nearly twenty years. Since that time a number of recombinant vaccinia-based vaccines have been developed for both veterinary(1-16) and human(17-27) use. Recent recombinant vaccinia vaccines for human use have focused on both cancer(18,19,21-24) and AIDS.(25-27) Several. reviews that summarize recent progress with poxvirus-based vaccines are available.(28-33) Over the years various anecdotal complications with vaccinia virus inoculations have been reported,(34-36) and other human safety concerns include potentially serious adverse consequences in immunocompromised individuals, and adverse reactions in a few normal individuals.(28) Other safety concerns relative to genetic changes in the virus also exist.(32) In view of these issues, some years ago the U.S. Army embarked on a program searching for small molecule drugs that could be used for the prevention or treatment of complications associated with the administration of either vaccinia virus itself or a recombinant vector derived from it. This report presents data on a series of compounds that we prepared as a part of that program.(37).

  DOI：

  10.1080/07328319808003478

文献信息

• A New Synthetic Route to 2-Deuterioadenines Substituted or Unsabustituted at the 9-Position
  作者：Tozo Fujii、Tohru Saito、Kyoko Kizu、Hiromi Hayashibara、Yukinari Kumazawa、Satoshi Nakajima

  DOI：10.3987/r-1986-09-2449

  日期：——
• Reactions of 9-Substituted 1-Aminoadenines with Nucleophiles and Syntheses of 3-Substituted 3<i>H</i>-Imidazo[4, 5-<i>e</i>][1, 2, 4]triazolo[1, 5-<i>c</i>][1, 2, 3]triazines
  作者：Shoji Asano、Keiji Itano、Yuriko Yamagata、Kohfuku Kohda

  DOI：10.1080/15257779408012163

  日期：1994.7

  Reactions of 1-aminoadenines (2) with NH2OH gave adenine 1-oxides (6). Alkaline treatment of 2 afforded 5-amino-4-(1,2,4-triazol-3-yl)imidazoles (3), which were converted to 3H-imidazo[4,5-e][1,2,4]triazolo[1,5-c][1,2,3]triazines (5), aza analogues o 3H-[1,2,4]triazolo[3,2-i]purines (4), by treatment with NaNO2.
• KRAUTH CHARLES A., SHORTANCY ANITA T., MONTGOMERY JOHN A., SECRIST III JO+, NUCLEOSIDES AND NUCLEOTIDES, 1989, 8, N5-6, 915-917
  作者：KRAUTH CHARLES A., SHORTANCY ANITA T., MONTGOMERY JOHN A., SECRIST III JO+

  DOI：——

  日期：——
• MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF
  申请人：modeRNA Therapeutics

  公开号：US20130123481A1

  公开（公告）日：2013-05-16

  The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using them.
• MULTI-SITE ADMINISTRATION
  申请人：MODERNA THERAPEUTICS

  公开号：US20130237593A1

  公开（公告）日：2013-09-12

  The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.